15.02
price up icon0.74%   0.11
after-market Dopo l'orario di chiusura: 15.00 -0.02 -0.13%
loading
Precedente Chiudi:
$14.91
Aprire:
$14.83
Volume 24 ore:
1.21M
Relative Volume:
0.66
Capitalizzazione di mercato:
$1.79B
Reddito:
$59.61M
Utile/perdita netta:
$-262.14M
Rapporto P/E:
-3.8316
EPS:
-3.92
Flusso di cassa netto:
$-247.49M
1 W Prestazione:
-2.97%
1M Prestazione:
+4.82%
6M Prestazione:
+8.45%
1 anno Prestazione:
+53.74%
Intervallo 1D:
Value
$14.76
$15.17
Intervallo di 1 settimana:
Value
$14.10
$15.78
Portata 52W:
Value
$7.86
$17.75

Arcutis Biotherapeutics Inc Stock (ARQT) Company Profile

Name
Nome
Arcutis Biotherapeutics Inc
Name
Telefono
805-418-5006
Name
Indirizzo
3027 TOWNSGATE ROAD, WESTLAKE VILLAGE, CA
Name
Dipendente
342
Name
Cinguettio
@ArcutisBio
Name
Prossima data di guadagno
2024-12-06
Name
Ultimi documenti SEC
Name
ARQT's Discussions on Twitter

Confronta ARQT con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
ARQT
Arcutis Biotherapeutics Inc
15.02 1.73B 59.61M -262.14M -247.49M -3.92
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
472.27 120.73B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
564.64 61.80B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
328.00 42.46B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
591.74 35.22B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
296.46 31.99B 3.81B -644.79M -669.77M -6.24

Arcutis Biotherapeutics Inc Stock (ARQT) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2024-12-30 Iniziato H.C. Wainwright Buy
2024-08-28 Iniziato Jefferies Buy
2024-01-03 Aggiornamento Mizuho Neutral → Buy
2023-10-26 Downgrade Mizuho Buy → Neutral
2023-10-13 Downgrade Goldman Buy → Neutral
2022-09-07 Iniziato Needham Buy
2022-03-17 Iniziato Goldman Buy
2021-06-30 Iniziato Mizuho Buy
2021-05-27 Aggiornamento Morgan Stanley Equal-Weight → Overweight
2020-11-09 Aggiornamento Goldman Neutral → Buy
2020-10-08 Iniziato Truist Buy
2020-02-25 Iniziato Cantor Fitzgerald Overweight
2020-02-25 Iniziato Cowen Outperform
2020-02-25 Iniziato Goldman Neutral
2020-02-25 Iniziato Guggenheim Buy
Mostra tutto

Arcutis Biotherapeutics Inc Borsa (ARQT) Ultime notizie

pulisher
Jul 23, 2025

Arcutis to Report Second Quarter 2025 Financial Results and Host Conference Call on August 6, 2025 - The Manila Times

Jul 23, 2025
pulisher
Jul 23, 2025

Is Arcutis Biotherapeutics (NASDAQ:ARQT) Using Too Much Debt? - 富途牛牛

Jul 23, 2025
pulisher
Jul 23, 2025

What analysts say about Arcutis Biotherapeutics Inc. stockFree Investment Community - Autocar Professional

Jul 23, 2025
pulisher
Jul 22, 2025

Arcutis Biotherapeutics Inc. Stock Analysis and ForecastExponential return rates - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 22, 2025

Is Arcutis Biotherapeutics Inc. a good long term investmentFree Capital Growth Strategies - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 22, 2025

What drives Arcutis Biotherapeutics Inc. stock priceAccelerated wealth building - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 21, 2025

Guggenheim maintains Buy rating on Arcutis Biotherapeutics stock amid prescription growth - Investing.com India

Jul 21, 2025
pulisher
Jul 20, 2025

(ARQT) Pivots Trading Plans and Risk Controls - news.stocktradersdaily.com

Jul 20, 2025
pulisher
Jul 17, 2025

Arcutis Biotherapeutics Completes Promising Psoriasis Treatment Study - TipRanks

Jul 17, 2025
pulisher
Jul 15, 2025

Is Arcutis Biotherapeutics (NASDAQ:ARQT) Weighed On By Its Debt Load? - simplywall.st

Jul 15, 2025
pulisher
Jul 14, 2025

Arcutis Bio EVP Burnett sells $432k in ARQT stock after option exercise - Investing.com Canada

Jul 14, 2025
pulisher
Jul 14, 2025

Arcutis’ ZORYVE Receives AAD Recommendation for Adult Atopic Dermatitis - MSN

Jul 14, 2025
pulisher
Jul 11, 2025

FDA News and Decisions: Midyear Updates - Dermatology Times

Jul 11, 2025
pulisher
Jul 10, 2025

Arcutis Biotherapeutics Stock Scores RS Rating Upgrade - MSN

Jul 10, 2025
pulisher
Jul 09, 2025

(ARQT) Investment Analysis - news.stocktradersdaily.com

Jul 09, 2025
pulisher
Jul 09, 2025

Arcutis Biotherapeutics - WBFF

Jul 09, 2025
pulisher
Jul 09, 2025

Uncovering Plaque Psoriasis: Exploring New FDA-Approved Topical Treatment - ABC Action News

Jul 09, 2025
pulisher
Jul 04, 2025

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

Jul 04, 2025
pulisher
Jul 03, 2025

Morgan Stanley assumes coverage of Arcutis Biotherapeutics stock with Overweight rating - Investing.com Nigeria

Jul 03, 2025
pulisher
Jul 03, 2025

Arcutis Awards Generous Stock Compensation Package: 14,000 RSUs for Two New Hires - Stock Titan

Jul 03, 2025
pulisher
Jun 27, 2025

Arcutis Biotherapeutics: A Closer Look At The Atopic Dermatitis Direction (NASDAQ:ARQT) - Seeking Alpha

Jun 27, 2025
pulisher
Jun 26, 2025

Arcutis Biotherapeutics (ARQT) Gains Strong AAD Recommendation for ZORYVE Cream | ARQT Stock News - GuruFocus

Jun 26, 2025
pulisher
Jun 26, 2025

ZORYVE Becomes Only Branded Topical to Earn Strong AAD Recommendation for Atopic Dermatitis - Stock Titan

Jun 26, 2025
pulisher
Jun 25, 2025

Arcutis Biotherapeutics: Another Approval Under Their Belt - Seeking Alpha

Jun 25, 2025
pulisher
Jun 23, 2025

Exploring 3 High Growth Tech Stocks In The US Market - simplywall.st

Jun 23, 2025
pulisher
Jun 18, 2025

When (ARQT) Moves Investors should Listen - news.stocktradersdaily.com

Jun 18, 2025
pulisher
Jun 18, 2025

Analysts Expect Breakeven For Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Before Long - Yahoo Finance

Jun 18, 2025
pulisher
Jun 17, 2025

Arcutis Biotherapeutics (ARQT) Announces Enrolling the First Child in Phase 2 Trials - MSN

Jun 17, 2025
pulisher
Jun 17, 2025

Arcutis Biotherapeutics Approves Key Proposals at Annual Meeting - TipRanks

Jun 17, 2025
pulisher
Jun 12, 2025

Arcutis: Out Of The Woods, Ready For Commercialization - Seeking Alpha

Jun 12, 2025
pulisher
Jun 11, 2025

10 Best Small-Cap Growth Stocks to Buy According to Analysts - Insider Monkey

Jun 11, 2025
pulisher
Jun 11, 2025

First child enrolled in Arcutis’ Phase II trial of cream for atopic dermatitis - Yahoo Finance

Jun 11, 2025
pulisher
Jun 10, 2025

Arcutis at Goldman Sachs Conference: Strategic Growth and Challenges By Investing.com - Investing.com South Africa

Jun 10, 2025

Arcutis Biotherapeutics Inc Azioni (ARQT) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$23.63
price up icon 3.32%
$36.59
price up icon 1.61%
$103.52
price up icon 0.08%
$27.57
price down icon 1.57%
$114.57
price down icon 0.03%
biotechnology ONC
$296.46
price up icon 0.55%
Capitalizzazione:     |  Volume (24 ore):